- Service Name
MIMETAS OrganoPlate
- Industry
Biotechnology, Drug Discovery, Organ-on-a-Chip Technology, Preclinical Research
- Main Value Proposition
MIMETAS offers advanced human tissue models that improve the efficiency and effectiveness of drug discovery, reducing costs and enhancing translatability.
- Description
MIMETAS develops organ-on-a-chip tissue and disease models that enhance drug discovery and development processes. Their innovative technology aims to provide more reliable and tailored medicines through advanced 3D modeling techniques.
- Key Features
OrganoReady program for optimized assays; Flexible fee-for-service solutions; Proprietary OrganoPlate platform for drug discovery; Tailored partnerships for drug discovery support
- Use Cases
Drug discovery and development for cancer therapies; Toxicology testing and safety assessments; Research in inflammatory bowel disease and other complex diseases; Development of immunotherapies using cell-based models
- Competitive advantages
Proprietary technology that enhances assay performance and reliability; Bespoke partnerships that cater to individual client needs; Strong focus on reducing reliance on animal models in research
- Strengths
MIMETAS's strengths lie in its innovative technology, commitment to customer collaboration, and expertise in 3D tissue modeling, which collectively drive significant advancements in therapeutic research.
- Positioning
MIMETAS positions itself as a leader in the organ-on-a-chip market, emphasizing its role in transforming drug discovery through innovative human tissue models.
- Audience
The primary target users include pharmaceutical companies, biotech firms, and academic researchers focused on drug discovery and development, particularly in oncology and complex disease modeling.
- CTA
Work With Us
- Tags
Organ-on-a-chip
Drug discovery
3D tissue models
Therapeutic innovation
- Tagline
Human Tissue Models for Better Therapies
- Tone of Voice
Innovative, collaborative, supportive
- Differentiation
MIMETAS stands out in the market by providing a unique combination of high-throughput organ-on-a-chip technology and tailored solutions that address specific research needs in drug discovery.
- Brand Positioning
MIMETAS embodies a brand identity centered on innovation, collaboration, and scientific excellence, aiming to empower researchers with cutting-edge tools for better therapeutic outcomes.
- Founded
2013-01-01
- Founders
Jos Joore
Paul Vulto
Thomas Hankemeier